Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab for acute uncomplicated vaso-occlusive episodes in sickle cell disease
NL-OMON59395Phase 1Completed
- Sponsor
- Roche
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sickle cell disease (SCD) comparing Crovalimab with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events, Change from baseline in targeted vital signs and clinical laboratory test results and 1 more. Started Sep 2023; status: completed.
02
Drugs
crovalimab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON59395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59395.